“Our hope is to be able to accurately diagnose several diseases at once with a single blood test in the future,” says Vogel, who led the study. He is an assistant professor, head of a research group, and part of the strategic research area MultiPark at Lund University.
Getting past the barrier surrounding the eye is a difficult but necessary part of treating retinoblastoma (RB)—a form of eye cancer that is more common in children. Once the barrier is penetrated, RB responds well to treatment. However, current methods, such as injections, chemotherapy, and radiotherapy, are painful and often cause vision loss and other serious side effects. But, a new method, described in a study published in Science Advances, might offer a safer, more effective way to treat RB.
HENDERSON, Nev., March 31, 2026 /PRNewswire/ — Restore Robotics today announced it has received additional 510(k) clearances from the U.S. Food and Drug Administration (FDA) for the remanufacturing of two more da Vinci Xi® robotic surgical instruments. This milestone expands Restore Robotics’ growing portfolio of cleared instruments and further strengthens its position as a leader in robotic instrument remanufacturing.
IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom
Garmin users can now integrate with the temperature-powered Natural Cycles app, which turns Garmin skin temperature data into fertility insights for women’s health
NEWTOWN, Conn., March 31, 2026 /PRNewswire/ — Elidah today announced FDA clearance of Elitone for Men, a non-invasive, at-home treatment designed to help men regain bladder control after prostate surgery, addressing a significant and often overlooked men’s health condition. Urinary incontinence, or bladder leakage, is one of the most common and disruptive complications following prostate procedures, yet men have had few options to actively support recovery at home.
DURHAM, N.C., March 31, 2026 /PRNewswire/ — Baebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A&B/SARS-CoV-2 Test, an ultra-rapid RT-PCR assay on the FINDER platform. This establishes FINDER as the first molecular point-of-care platform with multifunctional capabilities. The compact, automated system delivers PCR-quality results during the patient visit, with positives as early as 15 minutes and negatives in about 20 minutes, giving urgent care centers, emergency departments, clinics, and other decentralized settings the speed, ease of use, and reliability needed for better diagnostic decisions.
AUSTIN, Texas, March 31, 2026 /PRNewswire/ — Genesys Spine today announced the successful completion of the first surgical procedure utilizing the SIros-X System, a next-generation solution designed to deliver precision, adaptability, and control for complex sacroiliac joint fusion and pelvic fixation. The inaugural case was performed by Scott L. Parker, M.D., at Ascension Saint Thomas Hospital Midtown, Nashville, TN, marking an important milestone as the system begins clinical use.
Medtronic (NYSE:MDT) today announced CE mark approval and the first commercial European implants for its OmniaSecure system.
As spring approaches, a new type of cicada is emerging — not an insect, but a new variant of COVID-19.